Heterocyclic Compounds

Matches 51 - 100 out of 2,394	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2020/252222A1	PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).
WO/2020/216766A1	MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R1, R2, R2a, R3, Ra2, Ra4, Ra5, Ra6, Ra7, X1, X1a, A1 and A2 have the meaning...
WO/2020/117637A1	PRODRUGS OF QUINUCLIDINE RING-CONTAINING MUSCARINIC AGONISTS AND COMPOSITIONS AND METHODS THEREOF The present invention is directed to derivatives and prodrugs of quinuclidine-ring containing compounds. The present invention is further directed to ophthalmo!ogical compositions comprising a therapeutically effective amount of a compou...
WO/2020/096909A1	MATERIAL AND METHODS FOR THE TREATMENT OF GASTRO-INTESTINAL DISORDERS Provided herein is a bulk composition comprising the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt. Provi...
WO/2020/096911A1	METHODS OF PRODUCING NARONAPRIDE TRIHYDRATE Provided herein are methods of producing the trihydrate form of (3S, 4R, 3'R)-6-[4-(4-amino-5-chloro-2-methoxy-benzoylamino)-3-methox y-piperidin-1-yl]-hexanoic acid 1-azabicyclo[2.2.2]oct-3'-yl ester di-hydrochloride salt.
WO/2020/058458A1	QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT The invention relates to certain substituted quinuclidine-3-one compounds for use in the treatment of hyperproliferative disease, such as cancer, and diseases associated with inflammation. More particularly, the present invention relates...
WO/2020/039092A2	NOVEL AROMATIC MOLECULES The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
WO/2020/039094A1	PHENOXY(HETERO)ARYL ETHERS OF ANTIPROLIFERATIVE ACTIVITY The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
WO/2020/039088A2	NOVEL COMPOUNDS The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haemat...
WO/2020/001304A1	FXR RECEPTOR AGONIST The present invention falls within the field of medical technology, and in particular relates to a compound as shown in formula (I), and a pharmaceutically acceptable salt, ester or stereoisomer thereof, wherein R1, R2, X1, X2, X3, M, Ar...
WO/2019/243850A1	OXADIAZOLES AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions...
WO/2019/236699A1	MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in th...
WO/2019/223704A1	FUSED-CYCLIC PYRAZOLONE FORMAMIDE COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF Provided are a class of fused-cyclic pyrazolone formamide compounds and a preparation method therefor, a pharmaceutical composition and the use thereof. Specifically, provided is a compound having the structure as shown in formula (I) (w...
WO/2019/182938A1	AROMATIC ALDEHYDES WITH SUSTAINED AND ENHANCED IN VITRO AND IN VIVO PHARMACOLOGIC ACTIVITY TO TREAT SICKLE CELL DISEASE Compounds and methods for preventing and/or treating one or more symptoms of sickle cell diseases (SCD) by administering at least one of the compounds are provided. The compounds are based on vanillin which is chemically modified to incr...
WO/2019/173806A1	COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALT CANCER A method of treating a cancer in a patient includes obtaining a sample from the patient, using a C-circle assay to detect a presence of an alternative lengthening of telomeres (ALT) phenotype in the sample, and administering an effect am...
WO/2019/152946A1	COMPOUNDS FOR THE TREATMENT OF PAIN Provided herein are compounds that are useful in the treatment of pain in a subject.
WO/2019/121691A1	SULPHONYL UREA DERIVATIVES AS NLRP3 INFLAMMASOME MODULATORS The present disclosure relates to compounds of Formula (I): (I) and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for...
WO/2019/126253A1	ARYL AND HETEROARYL SUBSTITUTED INDOLE COMPOUNDS Disclosed are compounds of Formula (I) or salts thereof, wherein A, G, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmace...
WO/2019/122129A1	NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS The present invention encompasses compounds of formula (I) wherein the groups R1 to R4, A and p have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds...
WO/2019/126081A1	AMIDE SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS N-oxides, or salts thereof, wherein G, L2, R1, R5, R9, R10, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions...
WO/2019/126113A1	SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein G, A, R1, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, an...
WO/2019/118799A1	SUBSTITUTED INDOLE ETHER COMPOUNDS Disclosed are compounds of Formula (I) (I) N-oxides, or salts thereof, wherein R1, G, A, R5, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9...
WO/2019/118528A1	PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemperal dementia (FTD).
WO/2019/110521A1	FLUOROPHENYL SUBSTITUTED MUSCARINIC RECEPTOR LIGANDS WITH SELECTIVITY FOR M3 OVER M2 The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary di...
WO/2019/105881A1	METHOD FOR PRODUCING (3S)-3-(4-CHLOR-3-{[(2S,3R)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AM INO}PHENYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT The invention relates to a novel and improved method for producing (3S)-3-(4-chlor-3-{[(2S,3R)-2-(4-chlorphenyl)-4,4,4-trifluor -3-methylbutanoyl]amino}phenyl)-3-cyclo-propylpropanoic acid of the formula (I), to the compound of the formu...
WO/2019/086434A1	PROCESS FOR THE SYNTHESIS OF 2-BENZHYDRYL-3 QUINUCLIDINONE The present invention discloses a process for the preparation of 2-benzhydryl-3-quinuclidinone (1). (I). The process of the invention allows to obtain the intermediate 2-benzhydryl-3-quinuclidinone (1) by reaction of 2-benzylidene-3-quin...
WO/2019/015690A1	DEUTERATED 3-QUINUCLIDONE COMPOUND, PREPARATION METHOD, AND USE A deuterated 3-quinuclidone compound, a preparation method, and a use. In particular, the present invention provides a compound shown in general formula I or a pharmaceutically acceptable salt, isomer or a mixture thereof, solvate, polym...
WO/2018/220501A1	PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE The present invention relates to a process for the preparation of a novel and versatile synthesis intermediate and its use in the preparation of umeclidinium. The invention also relates to some reference standards allowing to detect impu...
WO/2018/210229A1	α-7 NICOTINE ACETYLCHOLINE RECEPTOR AGONIST AND APPLICATION THEREOF Disclosed are a series of α-7 nicotine acetylcholine receptor agonists, and specifically disclosed are compounds of formula (I), pharmaceutically acceptable salts thereof or tautomers thereof, and pharmaceutical uses thereof.
WO/2018/193463A1	AN IMPROVED PROCESS FOR THE PREPARATION OF TETRAHYDROISOQUINOLINE COMPOUNDS The present invention discloses an improved process for preparation of substantially pure pentamethylene bis(1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7- dimethoxy-1H-isoquinoline-2-propionate), a compound of formula I and its acid addition ...
WO/2018/163212A1	A PROCESS FOR THE PREPARATION OF UMECLIDINIUM BROMIDE AND INTERMEDIATES THEREOF Provided herein is a process for the preparation of umeclidinium bromide and intermediates thereof, wherein pure form of umeclidinium bromide is achieved by a two step process under mild conditions.
WO/2018/157277A1	ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS The present invention provides a compound of Formula (I), where in X is selected from the group consisting of CH and N; Q is selected from the group consisting of CH3 and H; R is selected from the group consisting of (II) and (III), or a...
WO/2018/150437A1	A PROCESS FOR PREPARING ACLIDINIUM BROMIDE AND INTERMEDIATES THEREOF Provided herein is a process for synthesis of aclidinium bromide and intermediates thereof, wherein the process for the preparation of aclidinium bromide increases the % yield of aclidinium bromide by about 70% to 90%.
WO/2018/152368A1	PYRROLO [1,2-B] PYRIDAZINE DERIVATIVES Provided is a compound of Formula (I), wherein the variable groups are defined herein.
WO/2018/108089A1	CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE Provided are a class of compounds, as represented by formula (I), having a bifunctional active quaternary ammonium salt structure of a β2 adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, ...
WO/2018/087561A1	PROCESS FOR THE PREPARATION OF UMECLIDINIUM BROMIDE The present invention discloses processes comprising a) reacting ethyl isonipecotate with 1 -bromo-2- chloroethane in the presence of an organic base in a solvent to form ethyl 1 -(2-chloroethyl)piperidine- 4-carboxylate (II) or a salt t...
WO/2018/011611A1	SALTS FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS The object of the invention relates to the salts of encenicline formed with inorganic and organic acids of general formula (I), as well as to the use of these for the production of pharmaceutical preparations primarily suitable for the t...
WO/2018/011227A1	INHIBITORS OF TRYPTOPHAN 2,3-DIOXYGENASE The invention relates to a compound of Formula I : Formula I, or pharmaceutically acceptable enantiomers, or salts thereof. The present invention also relates to the use of compounds of Formula (I) as selective inhibitors of tryptophan 2...
WO/2017/218920A1	ASYMMETRIC SYNTHESIS OF FUNAPIDE This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
WO/2017/200184A1	NOVEL CHIRAL PHASE-TRANSFER CATALYST, AND METHOD FOR PREPARING Α-AMINO ACID BY USING SAME The present invention relates to a novel chiral phase-transfer catalyst, and a method for preparing an α-amino acid by using the same. According to the present invention, an α-amino acid could be chirally synthesized in a high yield un...
WO/2017/176948A1	PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED ISOXAZOLINE COMPOUNDS - CRYSTALLINE TOLUENE SOLVATE OF (S)-AFOXOLANER This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine- based chiral phase transfer catalysts. The invention also relates to novel quinine-based phase transf...
WO/2017/148455A1	IODINATED ANALOGS OF CHOLINE, METHODS OF PREPARATION THEREOF, AND USE THEREOF AS MEDICAMENTS The invention relates to iodinated aromatic choline analogs of general formula wherein at least one R is iodine; the quaternary ammonium group comprises a hydroxyl substituent, and further substituent are as defined in the claims. The co...
WO/2017/120532A1	POLYMORPHS OF A PHOSPHATE SALT OF QUINUCLIDIN-4-YLMETHYL 4-METHYL-1H-INDOLE-3-CARBOXYLATE AND USES THEREOF Provided is a phosphate salt of quinuclidin-4-ylmethyl 4-methyl-1H-indole-3- carboxylate, in particular polymorphic Form A, a process for their preparation of said salt, in particular in polymorphic Form A, and a pharmaceutical compositi...
WO/2017/083242A1	INHIBITORS OF SUPPRESSION OF TUMORIGENCITY 2 (ST2) AND METHODS USING THE SAME Compounds capable of inhibiting suppression of tumorgenicity 2 (ST2) are disclosed. The compounds are useful in the treatment of a variety of diseases and conditions, such as alleviation of graft-versus-host disease (GVHD), cardiovascula...
WO/2017/075694A1	ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR The present invention relates to compounds of formula (I) wherein G1 to G8 are as defined herein. The compounds are PK inhibitors and as such represent a new approach to treating pathogenic infections, including multidrug resistant patho...
WO/2017/069226A1	NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND A compound represented by general formula [I] (in the formula, X represents N or the like, Y represents CH or the like, RA represents an optionally substituted cycloalkyl group or the like, R1 represents an alkyl group or the like, R2 re...
WO/2017/060287A1	PROCESS FOR THE PREPARATION OF ENCENICLINE FROM 7-CHLORO-BENZO[B]THIOPHENE-2-CARBOXYLIC ACID CHLORIDE AND (R)-QUINUCLIDIN-3-AMINE IN THE PRESENCE OF IMIDAZOLE The present invention relates to a process for the preparation of an amide from a carboxylic acid chloride and an organic molecule comprising both a primary amine group and a tertiary amine group, wherein the nitrogen atom of the tertiar...
WO/2017/060290A1	CRYSTALLINE ENCENICLINE HYDROCHLORIDE The present invention relates to a crystalline forms of encenicline hydrochloride and a process for their preparation. The invention also concerns a pharmaceutical compositions comprising an effective amount of the crystalline form of en...
WO/2017/051761A1	NOVEL PRODRUG The prodrug or a salt thereof according to the present invention is represented by the formula: D-X-L. (In the formula, D represents a useful compound and becomes D-X-H. X represents NR1, O, S, or Se. R1 represents a hydrogen atom, a sub...
WO/2017/023700A1	ANTITUSSIVE COMPOSITIONS AND METHODS Disclosed herein are compositions which include nicotinic receptor agonists, specifically of the α4β2 or α7 nAChR subtypes, and methods for treating or suppressing cough.

Matches 51 - 100 out of 2,394	< 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >